Search research articles
Contact Us
Filters
Showing results (81-90 of 146) with videos related to
Page
of 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
June 12, 2023
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Nobuyuki Katakami, Takashi Nishimura, Yu Hidaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
Akito Hata, Isamu Okamoto, Naoki Inui, et al.
Oncology and Therapy
|
March 5, 2022
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
Akito Hata, Yoshimasa Shiraishi, Naoki Inui, et al.
Radiation Oncology (London, England)
|
January 16, 2022
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 25, 2018
Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer
Kei Irie, Saori Shobu, Seika Hiratsuji, et al.
Bioorganic & Medicinal Chemistry
|
March 18, 2017
Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives
Koji Ono, Hiroshi Banno, Masanori Okaniwa, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 3, 2011
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2012
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Cancer Treatment and Research Communications
|
February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer
Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Cancer Chemotherapy and Pharmacology
|
May 1, 2015
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)
Akito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 146) with videos related to
Sort By:
Page
of 15
Lung Cancer (Amsterdam, Netherlands)
|
June 12, 2023
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Nobuyuki Katakami, Takashi Nishimura, Yu Hidaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
Akito Hata, Isamu Okamoto, Naoki Inui, et al.
Oncology and Therapy
|
March 5, 2022
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
Akito Hata, Yoshimasa Shiraishi, Naoki Inui, et al.
Radiation Oncology (London, England)
|
January 16, 2022
Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 25, 2018
Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer
Kei Irie, Saori Shobu, Seika Hiratsuji, et al.
Bioorganic & Medicinal Chemistry
|
March 18, 2017
Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives
Koji Ono, Hiroshi Banno, Masanori Okaniwa, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 3, 2011
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 18, 2012
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Cancer Treatment and Research Communications
|
February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer
Koichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Cancer Chemotherapy and Pharmacology
|
May 1, 2015
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)
Akito Hata, Nobuyuki Katakami, Shiro Fujita, et al.
Page
of 15